Question 1

What is Amphotericin B?

Accepted Answer

Amphotericin B is a Other.

Question 2

How often does Amphotericin B appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 7 articles.

Question 3

When was Amphotericin B first tracked by Ergen?

Accepted Answer

First tracked on May 21, 2026.

Question 4

When was Amphotericin B last mentioned in news?

Accepted Answer

Last active on May 21, 2026.

Question 5

What is Amphotericin B's current news sentiment?

Accepted Answer

Aggregate sentiment score: 10 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Amphotericin B in global news coverage?

Accepted Answer

Attention score of 2, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Amphotericin B?

Accepted Answer

Gilead, WHO Renew Visceral Leishmaniasis Partnership (May 21, 2026, 7 articles).

Question 8

How did the "Gilead, WHO Renew Visceral Leishmaniasis Partnership" event impact Amphotericin B?

Accepted Answer

Amphotericin B (amphotericin B) liposome for injection is the key product donated by Gilead Sciences to treat visceral leishmaniasis, with over 400,000 vials committed in the renewed agreement.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.